Table 4.
Endpoint of progression-free survival grouped by competing risks
| Idarubicin | Mitoxantrone | ||
|---|---|---|---|
| Treatment-related | 19 (17·4%) | 10 (9·7%) | |
| Second malignancy | 1 (0·9%) | 0 (0·0%) | |
| Treatment-related death | 18 (16·5%) | 10 (9·7%) | |
| Disease-related | 46 (42·2%) | 27 (26·2%) | |
| Refractory | 5 (4·6%) | 8 (7·8%) | |
| Second relapse | 38 (34·9%) | 17 (16·5%) | |
| Disease-related death | 3 (2·8%) | 2 (1·9%) | |
| Other death | 1 (0·9%) | 1 (1·0%) | |
| No events | |||
| Censored | 43 (39·4%) | 65 (63·1%) | |
Data are number (%) unless otherwise indicated. The number of disease-related deaths is low because most disease-related deaths occurred after a second relapse or after refractory disease, and hence do not constitute progression-free endpoints.